CRC
AXDX

Curi RMB Capital’s Accelerate Diagnostics AXDX Stock Holding History

Curi RMB Capital’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,340
Closed -$499K – 785
2018
Q4 		$499K Buy
+4,340
New +$643K 0.01% 636

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Curi RMB Capital's AXDX Position: Q1 2019 in Review

Curi RMB Capital sold out of Accelerate Diagnostics (AXDX) in Q1 2019, closing a stake of 4,340 shares — an estimated $499K sold.

Curi RMB Capital first reported a position in AXDX in Q4 2018 and held it in 1 quarter. The position peaked at $499K in Q4 2018. 114 funds tracked by Wall St. Rank hold AXDX as of Q1 2019.

  • Curi RMB Capital reported no remaining Accelerate Diagnostics position as of Q1 2019 after selling out during the quarter.
  • Curi RMB Capital sold 4,340 Accelerate Diagnostics shares in Q1 2019, an estimated $499K.
  • Curi RMB Capital first reported a position in Accelerate Diagnostics in Q4 2018 and held it in 1 quarter.
  • Curi RMB Capital's Accelerate Diagnostics position peaked at $499K in Q4 2018.
  • 114 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2019.

Based on Curi RMB Capital's 13F filing for Q1 2019, filed 15 May 2019.